Harvest Partners Announces Acquisition of AxelaCare Holdings, Inc
News Apr 16, 2013
Based in Lenexa, Kansas, AxelaCare is a full-service home infusion therapy provider. Therapies provided range from immune globulin (IG) therapy to antibiotics and nutrition therapy for patients across the United States. The Company also provides real value to practitioners, insurers and manufacturers through its proprietary outcomes management technology called CareLogix that monitors and measures the efficacy of IG therapy based on real-time outcomes and therapy response data.
AxelaCare's management team, including CEO Ted Kramm and President Kathee Kramm, will continue to lead the Company.
“Healthcare is a key area of interest for Harvest and we have been impressed by AxelaCare’s rapid rise to become the fifth largest provider of IG therapy in the U.S. in just four years," said Ira Kleinman, Senior Managing Director at Harvest Partners. “The company’s investment in processes, technology and people has led to an efficient, scaleable model with opportunity for continued growth as a larger share of the population seeks access to these vital services."
"We are pleased to partner with Ted and his team to guide the company's organic growth as well as to pursue strategic acquisitions that will build on AxelaCare's success,” added Jay Wilkins, Managing Director at Harvest.
“We are proud of our proprietary technology, CareLogix, which will ensure a positive patient experience and superior medical outcome in a home setting. CareLogix has been a key factor in our ability to attract new referral sources, manufacturers, insurers and patients, and we look forward to further developing the technology in conjunction with our partners at Harvest," said Ted Kramm, Chief Executive Officer.
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE
Some 30,000 Biomedical Publications Report on Misidentified CellsNews
Researchers from Radboud University have found more than 30,000 publications are reporting on the wrong cells.